Latest news
TECX: TX45 Phase 2 trial enrollment completed; topline results expected Q1 2027 - TradingViewTradingView · Thu, 06 Aug 2026 20:27:41 GMTDefinium Therapeutics reports $1.1B cash, $159.0M Q2 net loss and positive Phase 3 MDD topline - TradingViewTradingView · Thu, 06 Aug 2026 20:13:04 GMTAMLX: LUCIDITY trial for avexitide nears topline data; cash runway extends into 2028 - TradingViewTradingView · Thu, 06 Aug 2026 11:03:57 GMTKodiak's Trial Tests KSI-101 for Macular Edema Secondary to Inflammation - Stock TitanStock Titan · Thu, 06 Aug 2026 11:00:00 GMTPCVX: Phase 3 VAX-31 adult trials fully enrolled; OPUS-1 topline data expected Q4 2026 - TradingViewTradingView · Wed, 05 Aug 2026 20:23:25 GMTEyePoint reports Q2 loss of $94.5M, cash and investments $180M; LUGANO topline due Aug 2026 - TradingViewTradingView · Wed, 05 Aug 2026 11:13:00 GMTFTH: Strong cash position and clinical progress with PIKTOR, topline data expected by year-end 2026 - TradingViewTradingView · Tue, 04 Aug 2026 11:42:16 GMTTenax Therapeutics reports Q2 net loss $17.8M, cash $118.0M; LEVEL Phase 3 topline due Aug 2026 - TradingViewTradingView · Fri, 31 Jul 2026 11:33:00 GMT